The IUPAC–Richter Prize in Medicinal Chemistry has been established in 2006 by a generous gift from the Chemical Works of Gedeon Richter, Plc. (Budapest, Hungary) to acknowledge the key role that medicinal chemistry plays toward improving human health. The prize – USD 10000 – is to be awarded to an internationally recognized scientist, preferably a medicinal chemist, whose activities or published accounts have made an outstanding contribution to the practice of medicinal chemistry or to an outstanding example of new drug discovery.
The Prize are usually presented at a major international event where the recipient also gives a plenary lecture on the subject of his/her research.
Applicants are received by NOMINATION only, with just one person needing to serve in that capacity, although a total of five (5) individuals should be listed as referees overall. The submission should contain
a complete resume,
a professional autobiography of not more than two pages, and
a one-page summary of what the individual considers to be his/her activities, accomplishments and/or publications that have had the most significant impact upon the field of Medicinal Chemistry.
The material will be forwarded confidentially to an independent selection committee appointed by the IUPAC Subcommittee on Drug Discovery and Development.
2006 – Malcolm F.G. Stevens; announcement published in Chem. Int. Sep 2006, p.18; https://doi.org/10.1515/ci.2006.28.5.18a
2008 – Jan Heeres; announcement published in Chem. Int. July 2008, p. 20
2010 – Arun K. Ghosh; announcement published in Chem. Int. May 2010, p. 14
2012 – Stephen Hanessian; announcement published in Chem. Int. May 2012, p. 19
2014 – Helmut Buschmann; announcement published in Chem. Int. May 2014, p. 11; https://doi.org/10.1515/ci.2014.36.3.11a
2016 – Michael J. Sofia; announcement published in Chem. Int. May 2016, p. 27; News posted 2 Mar 2016
Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 3.7 billion (US$ 3.9 billion) by the end of 2016, Richter’s consolidated sales were approximately EUR 1.3 billion (US$ 1.4 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s healthcare field worldwide. Richter is also active in biosimilar product development.